Inhibitors of kallikrein in human plasma.
Human plasma was fractionated by ammonium sulfate precipitation, DEAE-cellulose chromatography, and Sephadex G-200 gel filtration to determine which method would give the greatest number of clearly separable kallikrein inhibitory peaks. With G-200 gel filtration three peaks could be separated which were demonstrated to contain alpha(2)-macroglobulin, C1 inactivator, and alpha(1)-antitrypsin. No other kallikrein inhibitors could be identified. The fractions containing C1 inactivator and alpha(2)-macroglobulin appeared to be more effective against kallikrein than that containing alpha(1)-antitrypsin. A patient with hereditary angioneurotic edema was shown to have an abnormal C1 inactivator protein capable of interfering with kallikrein's biologic, but not its esterolytic activity. Heat-treated human plasma, a commonly used source of kininogen for experiments with kallikrein, was shown to have kallikrein inhibitory activity.
D000510:Alpha-Globulins / Q000037:antagonists & inhibitors; D000645:Ammonium Sulfate; D000799:Angioedema / Q000097:blood / Q000235:genetics; D000818:Animals; D000906:Antibodies; D007611:Aprotinin / Q000097:blood*; D001681:Biological Assay; D011232:Chemical Precipitation; D002848:Chromatography, DEAE-Cellulose; D002850:Chromatography, Gel; D003169:Complement Inactivator Proteins; D004950:Esterases / Q000097:blood; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D007610:Kallikreins / Q000037:antagonists & inhibitors*; D051381:Rats; D014361:Trypsin Inhibitors / Q000037:antagonists & inhibitors; D014599:Uterus / Q000187:drug effects
D000510:Alpha-Globulins; D000906:Antibodies; D003169:Complement Inactivator Proteins; D007074:Immunoglobulin G; D014361:Trypsin Inhibitors; D007611:Aprotinin; D004950:Esterases; D007610:Kallikreins; D000645:Ammonium Sulfate